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Glucose-regulated protein of 78kD (GRP78) is a chaperone protein mainly located in the endoplasmic reticulum (ER). This
protein is normally present at low levels in adult cells but its expression is triggered by ER stress including glucose deprivation and
hypoxia. In tumor cells, it is overexpressed with fraction of protein found at the cell surface. This paper presents the physiology of
GRP78 in the context of ovarian cancer and its potential use as drug delivery systems targeting ovarian cancer cell.
1.Introduction
Glucose-regulated protein 78 (GRP78) is an endoplasmic
reticulum (ER) chaperone protein belonging to the heat sho-
ck protein 70 family. It consists of two functional domains,
a 44kDa N-terminal ATPase and a 20kDa C-terminal poly-
peptide-binding domain, and a variable 10kDa C-terminal
tail of unknown function.
This protein, as other members of this family, plays an
essential role in protein biosynthesis (for review, see [1]). It
facilitatesfoldingandassemblyofnewlysynthesizedproteins
and prevents intra- or intermolecular aggregation during
stress conditions [2, 3]. GRP78 expression is induced by a
variety of environmental and physiological stress conditions
leading to impairment of essential ER functions and home-
ostasis in order to protect organs and tissues against apopto-
sis [4]. Its expression also varies with developmental stages
and tissue speciﬁcity. A low basal level is identiﬁed in most
adult tissues whereas it is highly induced in cancer [5, 6].
GRP78expressionisinducedundersuchconditionsashypo-
xiaandnutrientdeprivation,partiallyexplainingitshighlev-
el in tumour cells [7].
GRP78 generally resides inside the ER lumen. However,
GRP78 is also found at the cell surface in a wide variety of
cancer cells, including neuroblastoma, lung adenocarcino-
ma, colon adenocarcinoma, ovarian tumour cells [8], pro-
state cancer [9], proliferating endothelial cells, and, more
generally, stressed tumour cells [10]. It is still unknown how
GRP78 localizes to the various cellular compartments, and
its physiological role at the cell surface membrane is still not
fully understood. A hypothesis is that upon GRP78 overex-
pression, it escapes to ER retention and reaches cell surface.
Some proteins are involved in GRP78 relocation, as MTJ-1
and Par-4 [11, 12]. Through its binding to other proteins
at the cell surface, GRP78 mediates cell-signalling pathways.
For example, cell surface GRP78 acts as a receptor for alpha-
2-macroglobulin, leading to activation of PAK-2, to induc-
tion of cell motility [12, 13], and to activation of MAPK and
PI3Kpathwayswhichpromoteproliferationandsurvivalina
variety of tumours [14, 15]. Other proteins have been identi-
ﬁed as partners of cell surface GRP78 such as Cripto I [16],
angiogenesis inhibitor plasminogen kringle 5 [17], Par-4
[18], or MHC-I molecule [19].
2.GRP78 andIts Role inCancer
In a variety of cancer cells and solid tumours (breast, lung,
prostate and ovarian cancers, melanoma, and glioma cells),2 Journal of Oncology
the level of GRP78 expression is highly induced and could
be essential for the survival of stressed cells such as cancer
cells. Its expression correlates with malignancy, metastasis
development, and drug resistance [9, 20–24]. It was shown
that knockdown of GRP78 inhibits tumour cell invasion in
vitro as well as tumour growth and metastasis aggressiveness
in xenograft models [25, 26], suggesting an important role
of GRP78 in cancer progression. However, the mechanism
whereby GRP78 promotes growth and metastasis is just
emerging. The presence of GRP78 at the cell surface of
highly metastatic cancer cells tends to suggest that it might
mediate signal transduction pathways inducing proliferation
and invasion [14].
In xenograft models treated with antivascular and anti-
angiogenic agents, GRP78 induction is most important in
tumourcellsborderingnecroticregionsinducedbythetreat-
ment [5]. Chemoresistance of various cancer cells correlates
with GRP78 expression and apoptosis inhibition [26–28].
This could be due to the fact that GRP78 can interact and
inhibit the activation of apoptosis pathway components as
described with caspase-7 [10]o rp 5 3[ 29]. It can also bind
to and inhibit the activation of BIK, BAX, and prevent cyto-
chrome c release from mitochondria [30–32]. Furthermore,
GRP78 forms a complex with other proteins and may indir-
ectly decrease the activity of proapoptotic components.
It was recently found that GRP78 could play another im-
portant role in cancer progression in regulating VEGF-in-
duced endothelial cell proliferation through the VEGF-
MAPK signal cascade [33].
3.GRP78Autoantibodies
GRP78 is overexpressed and relocated at cell surface of
various cancer cells. It represents a potent biomarker of cell
invasion, but its level may be too low to be detected in serum
of women diagnosed with cancer. Mintz et al. have demon-
strated the presence of GRP78 autoantibodies in patients
with prostate cancer and suggested that GRP78 could act
as a target of antibodies in these patients [9]. A strong and
speciﬁc positive correlation was observed between serum
reactivity to GRP78, development of metastatic androgen-
independent disease, and shorter overall survival. Moreover,
these antibodies do not seem to be increased in serum of pa-
tients with lung, breast, and ovarian cancer compared to
control, suggesting speciﬁcity towards prostate cancer [9].
However, GRP78 autoantibodies were also identiﬁed in sera
of mice bearing lung tumour as a model, and the titer was
associated with the detection of primary tumour and meta-
stases earlier than clinical identiﬁcation. These observations
suggest their potential utility in cancer detection and prog-
nosis [34]. GRP78 autoantibodies were detected in serum of
patients with gastric cancer, melanoma, and ovarian cancer
but it is not clear if their level increases with stage of disease
[35–38].
Circulating autoantibodies against GRP78 puriﬁed from
prostate cancer patients were able to bind to GRP78 express-
ed at the surface of tumour cells, to the same site as the
one recognized by its physiological agonist, the alpha2-
macroglobulin [39]. This binding promoted proliferation of
prostate cancer lines. Moreover, these antibodies protected
cellsfromapoptosis induced bytumour necrosis factoralpha
[39], suggesting that they could facilitate the emergence of
more aggressive prostate cancer cell phenotype. In contrast,
commercial antibodies against the C-terminus of GRP78
could act as antagonists and inhibit cellular proliferation and
promote apoptosis [15, 40]. This contradicting observation
suggests that the role of anti-GRP78 antibodies in tumour
development may be dependent on the nature of the GRP78
epitope recognized by the antibodies. Autoantibodies against
GRP78 isolated from serum of melanoma patients were also
found to promote tumour growth [41]. This activity could
depend on glycosylation of antibodies [36].
4.GRP78 inOvarianCancer
Epithelial ovarian cancer (EOC) accounts for the vast major-
ity of ovarian malignancies. EOC survival rate is dependent
on disease stage at the time of diagnosis. When diagnosed at
stage III or more advanced stage, the 5-year mortality rate
is close to 70% [42]. Due to the lack of speciﬁc symptoms
andreliableovariancancerbiomarkers,75%ofEOCpatients
haveadvancedstagediseaseatpresentation,makingEOCthe
most lethal gynecologic malignancy. The excellent survival
rates for women with early stage disease provide a strong
rationale to support research eﬀort in developing strategies
to identify the disease before it spreads outside the pelvis.
Currently, it remains a big challenge.
Recently, researches have moved away from cytotoxic
drugs to new targeted therapies, such as vascular endothelial
growth factor (VEGF) inhibition and other agents that inhi-
bit angiogenesis or cell-signaling pathways. Targeted therapy
is now coming to the forefront of research and clinical trials
in order to overcome resistance to cytotoxic drugs. The most
promising at this time are angiogenesis inhibitors. Deeper
understanding of cell-signaling pathways in ovarian cancer is
needed to develop innovative strategies to improve outcome
of EOC patients.
Despite the great interest of GRP78 in cancer develop-
ment and progression, few data is available on GRP78 and
ovariancancer.FirstevidenceofGRP78asantigenassociated
with ovarian cancer was brought in 1997 by the detec-
tion of humoral immune response to GRP78 in ovarian can-
cer patients [43]. This presence is certainly associated to
the expression of membrane GRP78 in ovarian cancer cells
[8, 44]. Sera from ovarian cancer patients failed to recognize
GRP78 on normal ovarian tissue suggesting that this antigen
is unique to cancer [43]. However, Mintz et al. described the
presence of GRP78 autoantibodies in serum of control fe-
male and the lack of diﬀerence between the level in ovarian
cancer and control patients [9]. The same observation was
recently reported by Lu et al. [44]. The level of GRP78 auto-
antibodies remains controversial since it was recently sug-
gested that GRP78 autoantibodies increased with ovarian
cancer stage [37] whereas Cohen and Petignat described the
opposite[35].Theremightbeavarietyofreasonswhyresults
are diﬀerent, such as the methods of GRP78 autoantibodies
detection (ELISA or immunoblot) or diﬀerent sample size.Journal of Oncology 3
If some authors focused on GRP78 autoantibodies as
prognostic marker of ovarian cancer, none reported a possi-
ble correlation between GRP78 level in ovarian cancer tissue
and disease stage and chemotherapy resistance as suggested
in lung and breast cancer, melanoma, and glioma cells [27,
28, 45–47].
5. GRP78 as a Recognition Element for
DrugTargeting inOvarianCancer
Targeted therapy consists in the design and application of
drugs speciﬁcally directed against well-deﬁned targets that
are critical for tumor survival and not compromising for
normal organs and tissues. It may also involve the recogni-
tion of a molecular entity speciﬁc to the organ or cells of
interest. This strategy takes all its sense when cancer mass
is spread as micrometastasis as encountered in ovarian can-
cer.Speciﬁclocalisationtothecancercellswillmoreoverpro-
vide safer therapy by reducing the high toxicity of chemothe-
rapeutic drugs and the adverse eﬀects related to the unfavo-
urable biodistribution to both cancerous and healthy tissues.
Targeted therapy is usually mediated via a ligand speciﬁc to
a molecular target overexpressed or ideally exclusively ex-
pressed at the cells of interest.
GRP78 represents a very interesting target to be associ-
ated with drug delivery systems, as it is speciﬁcally expressed
at cancer cell membranes.
Arap et al. designed two ligand peptides to speciﬁcally
bind to the GRP78 expressed at cell surface [48]. After intra-
venous administration, these peptides were shown to be able
to target prostate or breast cancer cells implanted in mice
modelswhereastheywerenotdetectedinhealthytissues.The
ligand peptides were linked to a proapoptotic peptide before
systemic administration to tumour-bearing mice weekly for
4 weeks. Tumour volume was signiﬁcantly smaller in chi-
mera-treated groups compared to animals receiving either
the vehicle or unconjugated mixture of the ligand peptides
with the proapoptotic peptide.
In another study, GRP78 was identiﬁed as the receptor
for the best candidate of a cohort of cyclic peptides scre-
ened for internalisation in melanoma cell lines, the “Pep42”
[49]. After combination with quantum dots, cellular uptake
and ER localisation of the conjugate were observed in
vitro. Furthermore, direct combination of the cyclic peptide
with taxol leads to an increased apoptosis rate in vitro in
melanoma cells compared to free taxol. A control construct
where taxol was conjugated to a linear peptide analogue had
aw e a k e re ﬀect compared to taxol alone. The ability of Pep42
to selectively bind to human cancer cells was further test-
ed with melanoma cells (Me6652/4), lung adenocarcinoma
cells (A549), osteosarcoma cells (SJSA-1), hepatoma cells
(HepG2), and two normal ﬁbroblast cell lines [50]. The pep-
tide bound to cancerous cells whereas only limited recogni-
tion was observed with normal cells. Selective apoptosis was
induced in cancer cells and not in normal cells when Pep42
was linked to a proapoptotic peptide. Pep42 conjugated
with quantum dots were administered to tumour-bearing
animals. The conjugates concentrated in the tumour tissue
without accumulation in other organs, demonstrating the
speciﬁcity of the targeting.
These data support that cancer cells expressing the
GRP78 at their surface are more sensitive to cytotoxic drugs
when these are conjugated to recognition elements target-
ing the GRP78. Direct ligation of a ligand to a drug molecule
is a common mean to achieve targeting. However, it needs
chemical modiﬁcation of the active compound and the fur-
therreleaseofthedrugthatmaycompromisethepharmacol-
ogical eﬃciency. Therefore, other approaches involving syn-
thetic drug carriers have been developed. The drug is encap-
sulated or associated with a polymer or lipid core that is de-
corated at its surface with a recognition moiety.
Pegylated liposomes were surface-modiﬁed by Katanasa-
ka et al. [33] with the peptide developed by Arap et al. [48].
It was shown in vitro that the liposomes were able to target
VEGF-activated HUVEC cells as well as DU145, a prostate
cancer cell line [48]. Biodistribution studies in mice demon-
strated a preferable localisation of the targeted liposomes to
the vasculature and the tumour tissue with no accumulation
in normal tissues except for the spleen. Furthermore, the
targeted liposomes were loaded with doxorubicin. In the
dorsal air pouch model in mice implanted with C26 tum-
ours, these liposomes suppressed the tumour-induced vas-
cularisationangiogenesiswhereasuntargetedliposomeswere
not as eﬃcient. Survival rate was also signiﬁcantly increased
in mice treated with targeted liposomes compared to sucrose
solutionoruntargetedliposomes.Thisstudyshowstheinter-
est of using GRP78 as a target element to bring large amount
of drug to a tumour via colloidal carriers. It also shows
that GRP78 can be a target for cancer antineovascularisation
therapy.
A more recent study reports the development of paclita-
xel-loadedpolyesternanoparticlesconjugatedwithaGRP78-
recognising peptide [51]. This approach proved to increase
paclitaxel concentration and apoptosis in irradiated breast
carcinoma in mice for up to 3 weeks. No signiﬁcant tumour
growthdelaywasobservedwhenfreepaclitaxeloruntargeted
nanoparticles were used after irradiation compared to irradi-
ation alone.
These studies strengthen the signiﬁcance of using GRP78
as a targeting moiety for the development of more eﬃcient
anticancer treatments. So far, to our knowledge, only pepti-
des have been used as recognising entity, and no studies
on ovarian cancer has been reported. Antibodies against
GRP78 may be used for their targeting capacities; however,
they can also be of advantage as antitumoral agent as was
demonstrated by Cohen and Petignat [35] .A sp r o o fo fp r i n -
ciple, we recently combined paclitaxel-loaded nanoparticles
with anti-KDEL (NPs-Tx-KDEL) antibodies (unpublished
data). Brieﬂy, the results showed that antibody-coated parti-
cles presented a higher binding to the cells even though the
internalization rate appeared limited. Moreover, despite the
fact that KDEL antibodies exhibit unforeseen antiapoptotic
properties (in the opposite to puriﬁed GRP78 autoanti-
bodies), NPs-Tx-KDEL signiﬁcantly increased sensitivity
of Bg-1, an ovarian cancer cell line, to the drug compared
to other treatments (free paclitaxel, unloaded carrier, or
untargeted nanoparticles).4 Journal of Oncology
In summary, GRP78 appears of great interest as prog-
nostic marker and therapeutic target for various types of
cancer. Exciting data have been gathered regarding its role
in the development of cancer, and a few studies have shown
interesting prospective in using this antigen as a receptor for
targeted therapy. Nevertheless, very few studies investigated
GRP78 and anti-GRP78 autoantibodies in ovarian cancer. If
potentiality for this protein has been suggested, no data is
so far available to show its interest as marker or therapeutic
targetofovariancancer.Developmentoftargeteddrugdeliv-
ery systems oﬀers the possibility to deliver a high concen-
tration of chemotherapeutic agents to the right place. Fur-
thermore, if chosen wisely, the antibodies against the GRP78
may have anticancer activity by themselves.
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